JPMorgan Downgrades Chimerix (CMRX) to Underweight

JPMorgan downgraded Chimerix (NASDAQ: CMRX) from Neutral to Underweight.

Analyst Cory Kasimov remains optimistic on biotech names for 2018 in the face of recent volatility. The analyst makes adjustments across his coverage universe to better identify higher conviction names in the face of M&A speculation and broader market volatility.

For an analyst ratings summary and ratings history on Chimerix click here. For more ratings news on Chimerix click here.

Shares of Chimerix closed at $4.93 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
• Owens Corning (OC) PT Raised to $182 at Argus
• Macquarie Upgrades ASM Pacific Technology (522:HK) (ASMVY) to Outperform